JAK1 and alopecia areata: tested biomarkers of scalp alopecia areata in patients who participated in the clinical trial (31), presenting that although brepocitinib can directly inhibit IFN-γ signaling through JAK1/2 activation, ritlecitinib can indirectly affect IFN-γ production through inhibition of TEC family kinases.